Advanced search
Publication Cover
Expert Opinion on Therapeutic Patents Volume 19, 2009 - Issue 12
Submit an article Journal homepage
234
Views
15
CrossRef citations to date
0
Altmetric
Reviews

Luteinizing hormone-releasing hormone antagonists

Gábor Mező Eötvös Loránd University, Hungarian Academy of Sciences, Research Group of Peptide Chemistry, 1117 Budapest, Pázmány P. stny. 1/A, Hungary +36 1 209 1433; +36 1 372 2620; [email protected]
&
Marilena Manea University of Konstanz, Department of Chemistry, Laboratory of Analytical Chemistry and Biopolymer Structure Analysis, 78457 Konstanz, Germany; University of Konstanz, Zukunftskolleg, 78457 Konstanz, Germany
Pages 1771-1785 | Published online: 26 Nov 2009

Bibliography

  • Matsuo H, Baba Y, Nair RM, Structure of the porcine LH- and FSH-releasing hormone. I. The proposed amino acid sequence. Biochem Biophys Res Commun 1971;43:1334-9
  • Kastin AJ, Coy DH, Schally AV, Zadina JE. Dissociation of effects of LH-RH analogs on pituitary regulation and reproductive behavior. Pharmacol Biochem Behav 1980;13:913-4
  • Carmel PW, Araki S, Ferin M. Pituitary stalk portal blood collection in rhesus monkeys: evidence for pulsatile release of gonadotropin-releasing hormone (GnRH). Endocrinology 1976;99:243-8
  • Redding TW, Kastin AJ, Gonzales-Barcena D, The half-life, metabolism and excretion of tritiated luteinizing hormone-releasing hormone (LH-RH) in man. J Clin Endocrinol Metab 1973;37:626-31
  • Belchetz PE, Plant TM, Nakai Y, Hypophysial responses to continuous and intermittent delivery of hypopthalamic gonadotropin-releasing hormone. Science 1978;202:631-3
  • Schultze-Mosgau A, Griesinger G, Altgassen C, New developments in the use of peptide gonadotropin-releasing hormone antagonists versus agonists. Expert Opin Investig Drugs 2005;14:1085-97
  • Millar RP. GnRHs and GnRH receptors. Anim Reprod Sci 2005;88:5-28
  • Schally AV, Nagy A. New approaches to treatment of various cancers based on cytotoxic analogs of LHRH, somatostatin and bombesin. Life Sci 2003;72:2305-20
  • Padula AM. GnRH analogues – agonists and antagonists. Anim Reprod Sci 2005;88:115-26
  • Coccia ME, Comparetto C, Bracco GL, Scarselli G. GnRH antagonists. Eur J Obstet Gynecol Reprod Biol 2004;115S:44-56
  • Huirne JA, Homburg R, Lambalk CB. Are GnRH antagonists comparable to agonists for use in IVF? Hum Reprod 2007;22:2805-13
  • Reissmann T, Schally AV, Bouchard P, The LHRH antagonist cetrorelix: a review. Hum Reprod Update 2000;6:322-31
  • Trachtenberg J. Emerging pharmacologic therapies for prostate cancer. Rev Urol 2001;3:S23-8
  • Schmidt F, Sundaram K, Thau RB, Bardin CW. [Ac-D-NAL(2)1,4FD-Phe2,D-Trp3,D-Arg6]-LHRH, a potent antagonist of LHRH, produces transient edema and behavioral changes in rats. Contraception 1984;29:283-9
  • Bajusz S, Csernus VJ, Janáky T, New antagonists of LHRH. II. Inhibition and potentiation of LHRH by closely related analogues. Int J Pept Protein Res 1988;32:425-35
  • Cook T, Sheridan WF. Development of GnRH antagonists for prostate cancer: new approaches to treatment. Oncologist 2000;5:162-8
  • Nestor JJ Jr, Tahilramani R, Ho TL, Potent gonadotropin releasing hormone antagonists with low histamine-releasing activity. J Med Chem 1992;35:3942-8
  • Jiang G, Stalewski J, Galyean R, GnRH antagonists: a new generation of long acting analogues incorporating p-ureido-phenylalanines at positions 5 and 6. J Med Chem 2001;44:453-67
  • Deghenghi R, Boutignon F, Wüthrich P, Lenaerts V. Antarelix (EP 24332) a novel water soluble LHRH antagonist. Biomed Pharmacother 1993;47:107-10
  • Beckers T, Bernd M, Kutscher B, Structure-function studies of linear and cyclized peptide antagonists of the GnRH receptor. Biochem Biophys Res Commun 2001;289:653-63
  • Janecka A, Janecki T, Shan S, Novel, potent luteinizing hormone-releasing hormone antagonists withis in water. J Med Chem 1994;37:2238-41
  • Phillips A, Hahn DW, McGuire JL, Evaluation of the anaphylactoid activity of a new LHRH antagonist. Life Sci 1988;43:883-8
  • Rivier JE, Jiang G, Porter J, Gonadotropin-releasing hormone antagonists: novel members of the azaline B family. J Med Chem 1995;38:2649-62
  • Rivier J, Porter J, Hoeger C, Gonadotropin-releasing hormone antagonists with N- omega-triazolylornithine, -lysine, or -p-aminophenylalanine residues at positions 5 and 6. J Med Chem 1992;35:4270-8
  • Herbst KL. Gonadotropin-releasing hormone antagonists. Curr Opin Pharmacol 2003;3:660-6
  • Huhtainemi I, White R, McArdle CA, Persson B-E. Will GnRH antagonists improve prostate cancer treatment? Trends Endocrinol Metabol 2008;20:43-50
  • Debruyne F, Gres AA, Arustamov DL. Placebo-controlled dose-ranging phase 2 study of subcutaneously administered LHRH antagonist cetrorelix in patients with symptomatic benign prostatic hyperplasia. Eur Urol 2008;54:170-7
  • Kovács M, Szepesházi K, Schally AV. Endocrine and antineoplastic effects of antagonistic and cytotoxic analogs of luteinising hormone-releasing hormone. In: Kovács M, Merchenhalter I, editors, Neuropeptides and peptide analogs. Research Signpost, Kerela, India; 2009. p. 33-57
  • Weckermann D, Harzman R. Hormone therapy in prostate cancer: LHRH antagonists versus LHRH analogues. Eur Urol 2004;46:279-84
  • Broqua P, Riviere PJ, Conn PM, Pharmacological profile of a new, potent, and long-acting gonadotropin-releasing hormone antagonist: degarelix. J Pharmacol Exp Ther 2002;301:95-102
  • Ferring BV. GnRH antagonists. US5925730; 1999
  • Bernd M, Kutscher B, Gunther E, Methods of treatment using novel LHRH antagonists having improved solubility properties. US20060281685; 2006
  • Kissei Pharmaceutical Co., Ltd. Fused heterocyclic derivative, medicinal composition containing the same, and medicinal use thereof. EP1939204; 2008, WO2007046392; 2007
  • Ardana Bioscience Ltd. Sustained release of microcrystalline peptide suspension. US20060229238; 2006
  • Praecis Pharmaceutical, Inc. Pharmaceutical formulations for sustained drug delivery. WO2007022254; 2007
  • AEterna Zentaris GmbH. Application of initial doses LHRH analogues and maintenance doses of LHRH antagonists for the treatment of hormone-dependent cancers and corresponding pharmaceutical kits. WO2008017664; 2008, US20080032935; 2008, EP1891964; 2008
  • Balance Pharmaceutical, Inc. Nasal-spray formulation and method. US6958142; 2005
  • AEterna Zentaris GmbH. Injectable solution of an LHRH antagonist. US7214662; 2007
  • Edwards RG, Lobo R, Bouchard P. Time to revolutionize ovarian stimulation. Hum Reprod 1996;11:917-9
  • Janssens RM, Lamback CB, Vermeiden JP, Dose-finding study of triptorelin acetate for prevention of premature LH surge in IVF: a prospective, randomized, double-blind, placebo-controlled study. Hum Reprod 2000;15:2333-40
  • Tarlatzis BC, Fauser BC, Kolibianakis EM, GnRH antagonists in ovarian stimulation for IVF. Hum Reprod Update 2006;12:333-40
  • Fauser BC, Devroey P, Macklon NS. Multiple birth resulting from ovarian stimulation for subfertility treatment. Lancet 2005;365:1807-16
  • Verberg MF, Macklon NS, Nargund G, Mild ovarian stimulation for IVF. Hum Reprod Update 2009;15:13-29
  • AEterna Zentaris GmbH. LHRH-antagonists in the treatment of fertility disorders. US7393834; 2008
  • Mező G, Manea M, Szabó I, New derivatives of GnRH as potential anticancer therapeutic agents. Curr Med Chem 2008;15:2366-79
  • Brawer MK. The evolution of hormonal therapy for prostatic carcinoma. Rev Urol 2001;3S:1-9
  • Emons G, Gründker C, Günthert AR, GnRH antagonists in the treatment of gynecological and breast cancers. Endocr Relat Cancer 2003;10:291-9
  • Keller G, Schally AV, Gaiser T, Receptors for luteinizing hormone releasing hormone (LHRH) expressed in human non-Hodgkin's lymphomas can be targeted for therapy with cytotoxic LHRH analogue AN-207. Eur J Cancer 2005;41:2196-202
  • Gründker C, Günthert AR, Westphalen S, Emons G. Biology of the gonadotropin-releasing hormone system in gynecological cancers. Eur J Endocrinol 2002;146:1-14
  • Leung PC, Choi JH. Endocrine signaling in ovarian surface epithelium and cancer. Hum Reprod Update 2007;13:143-62
  • Conn PM, Crowley WF Jr. Gonadotropin-releasing hormone and its analogs. Annu Rev Med 1994;45:391-405
  • Sealfon SC, Weinstein H, Millar RP. Molecular mechanisms of ligand interaction with the gonadotropin-releasing hormone receptor. Endocr Rev 1997;18:180-205
  • Gründker C, Völker P, Günthert AR, Emons G. Antiproliferative signaling of LHRH in human endometrial and ovarian cancer cells through G-protein αi-mediated activation of phosphotyrosine phosphatase. Endocrinology 2001;142:2369-80
  • Maudsley S, Davidson L, Pawson AJ, Gonadotropin-releasing hormone (GnRH) antagonists promote proapoptotic signaling in peripheral reproductive tumor cells by activating a Galphai-coupling state of the type I GnRH receptor. Cancer Res 2004;64:7533-44
  • Gründker C, Schlotawa L, Viereck V, Antiproliferative effects of the GnRH antagonist cetrorelix and of GnRH-II on human endometrial and ovarian cancer cells are not mediated through the GnRH type I receptor. Eur J Endocrinol 2004;151:141-9
  • Fister S, Günthert AR, Emons G, Gründker C. Gonadotropin-releasing hormone type II antagonists induce apoptotic death in human endometrial and ovarian cancer cells in vitro and in vivo. Cancer Res 2007;67:1750-6
  • Nagy A, Schally AV, Armatis P, Cytotoxic analogs of luteinizing hormone-releasing hormone containing doxorubicin or 2-pyrrolinodoxorubicin, a derivative 500-1000 times more potent. Proc Natl Acad Sci USA 1996;93:7269-73
  • Tulane Educational Fund. Targeted cytotoxic anthracycline analogs. US6184374; 2001
  • AEterna Zentaris GmbH. Conjugates of disorazoles and their derivatives with cell-binding molecules, novel disorazole derivatives, processes of manufacturing and uses thereof. US20080090758; 2008
  • Szabó I, Manea M, Orbán E, Development of an oxime bond containing daunorubicin-gonadotropin-releasing hormone-III conjugate as a potential anticancer drug. Bioconjug Chem 2009;20:656-65
  • Tulane Educational Fund. LHRH antagonists. US5198533; 1993
  • Reissmann T, Engel J, Kutscher B, The LHRH antagonist Cetrorelix. Drugs Future 1994;19:228-37
  • AEterna Zentaris GmbH. Preparation and use of oligopeptide lyophilisate for gonad protection. US6867191; 2005
  • AEterna Zentaris GmbH. Method for producing steril suspensions or lyophilisates of poorly soluble basic peptide complexes, pharmaceutical formulations containing the same, and use thereof as medicaments. WO2006069641; 2006
  • Asta Medica Aktiengesellschaft. Immobilized and activity-stabilized complexes of LHRH antagonists and processes for their preparation. US6022860; 1998
  • Matikainen T, Ding YQ, Vergara M, Differing responses of plasma bioactive and immunoreactive follicle-stimulating hormone and luteinizing hormone to gonadotropin-releasing hormone antagonist and agonist treatments in postmenopausal women. J Clin Endocrinol 1992;7:820-5
  • Olivennes F, Cuncha-Filho JS, Fanchin R, The use of GnRH antagonists in ovarian stimulation. Hum Reprod Update 2002;8:279-90
  • Gonzalez-Barcena D, Alvarez RB, Ochoa EP, Treatment of uterine leiomyomas with luteinizing hormone-releasing hormone antagonist Cetrorelix. Hum Reprod 1997;12:2028-35
  • Comaru-Schally AM, Brannan W, Schally AV, Efficacy and safety of luteinizing hormone-releasing hormone antagonist cetrorelix in the treatment of symptomatic benign prostatic hyperplasia. J Clin Endocrinol Metab 1998;83:3826-31
  • Telegdy G, Tanaka M, Schally AV. Effects of the LHRH antagonist Cetrorelix on the brain function in mice. Neuropeptides 2009;43:229-34
  • AEterna Zentaris GmbH. Treatment of dementia and neurodegenerative diseases with intermediate doses of LHRH antagonists. US7288517; 2007
  • Ben-Josef E, Yang SY, Ji TH, Hormone-refractory prostate cancer cells expresses functional follicle-stimulating hormone receptor (FSHR). J Urol 1999;161:970-6
  • Praecis Pharmaceuticals, Inc. Methods for treating FSH related conditions with GnRH antagonists. US7109171; 2007
  • Tomera K, Gleason D, Gittelman M, The gonadotropin-releasing hormon antagonist abarelix depot versus luteinizing hormone releasing hormone agonists leuprolide or goserelin: initial results of endocrinological and biochemical efficacies in patients with prostate cancer. J Urol 2001;165:1585-9
  • Wong SL, Lau DT-W, Baughman SA, Pharmacokinetics and pharmacodynamics of abarelix, a gonadotropin releasing hormone (GnRH) antagonists after subcutaneous, continuous infusion in patients with prostate cancer. Clin Pharmacol Ther 2003;73:304-11
  • Praecis Pharmaceuticals, Inc. Pharmaceutical formulations for sustained drug delivery. US5968895; 1999
  • Wong SL, Lau DT-W, Baughman SA, Pharmacokinetics and pharmacodynamics of a novel depot formulation of abarelix, a gonadotropin releasing hormone (GnRH) antagonists, in healthy men ages 50 to 75. J Clin Pharmacol 2004;44:495-502
  • Van Poppel H, Nilsson S. Testosteron surge: rationale for gonadotropin-releasing hormon blockers? Urology 2008;71:1001-6
  • Steiner MS, Veverka KA. Composition comprising a SARM and GnRH agonist or an GnRH antagonist, and methods of use thereof. US20060287282; 2006
  • Felberbaum R, Diedrich K. Ovarian stimulation for in-vitro fertilization/intracytoplasmic sperm injection with gonadotrophins and gonadotrophin-releasing hormone analogues: agonists and antagonists. Hum Reprod 1999;14:207-21
  • Meldrum DR, Scott RT, Levy MJ, Oral contraceptive pretreatment in women undergoing controlled ovarian stimulation in ganirelix acetate cycles may, for a subset of patients, be associated with low serum luteinizing hormone levels, reduced ovarian response to gonadotropins and early pregnancy loss. Fertil Steril 2009;91:1963-5
  • Bellver J, Albert C, Lambarta E, Pellicer A. Early pregnancy loss in women stimulated with gonadotropin-releasing hormone antagonist protocols according to oral contraceptive pretreatment. Fertil Steril 2007;87:1098-101
  • Meldrum DR, Cassidenti DL, Rosen GF, Oral contraceptive pretreatment and half dose of ganirelix does not excessively suppress LH and may be an excellent choice for scheduling IUI cycles. J Assist Reprod Genet 2008;25:417-20
  • Rivier J. GnRH analogues towards the next millenium. In: Lunenfeld B, editor, GnRH Analogues – TheState of Art at the Millenium; Parthenon Publishing: Carnforth, UK; 1999. p. 31-45
  • Haviv F, Fitzpatrick TD, Nichols CJ, The effect of of NMeTyr5 substitution in luteinizing hormone-releasing hormone antagonists. J Med Chem 1993;36:928-33
  • Ferring BV. GnRH antagonists being modified in positions 5 and 6. WO1998046634; 1998, US6214798; 2001
  • Doehn C, Sommerauer M, Jocham D. Drug evaluation: degarelix – a potential new therapy for prostate cancer. IDrugs 2006;9:565-72
  • Klotz L, Boccon-Gibod L, Shore ND, The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in prostate cancer patients. BJU Int 2008;102:1531-8
  • Persson B-E, Olesen TK, Jensen J-K. Degarelix: a new approach for the treatment of prostate cancer. Neuroendocrinology 2009;90:235-44
  • Doehn C, Sommerauer M, Jocham D. Degarelix and its therapeutic potential in the treatment of prostate cancer. Clin Intervent Aging 2009;4:215-23
  • Samant MP, Gulyas J, Hong DJ, Iterative approach to the discovery of novel degarelix analogues: substitutions at positions 3, 7, and 8. Part II. J Med Chem 2005;48:4851-60
  • Samant MP, Gulyas J, Hong DJ, Synthesis, in vivo and in vitro biological activity of novel azaline B analogs. Bioorg Med Chem Lett 2005;15:2894-7
  • AEterna Zentaris GmbH. LHRH antagonists having improved solubility properties. US7148195; 2006
  • AEterna Zentaris GmbH. Use of LHRH antagonists for the treatment of lower urinary tract symptoms, in particular overactive bladder and/or detrusor overactivity. EP1967202; 2008
  • Pelletier JC, Chengalvala M, Cottom J, 2-Phenyl-4-piprazinylbenzimidazoles: Orally active inhibitors of the gonadotropin releasing (GnRH) receptor. Bioorg Med Chem 2008;16:6617-40
  • Heitman LH, Ijzerman AP. G protein-coupled receptors of the hypothalamic-pituitary-gonadal axis: a case for GnRH, LH, FSH, and GPR54 receptor ligands. Med Res Rev 2008;28:975-1011
  • Betz SF, Zhu YF, Chen C, Struthers RS. Non-peptide gonadotropin-releasing hormone receptor antagonists. J Med Chem 2008;51:3331-48
  • Neurocrine Biosciences, Inc. Gonadotropin-releasing hormone receptor antagonists and methods relating thereto. WO2005007633; 2005, US7229995; 2007
  • Chen C, Wu D, Guo Z, Discovery of sodium R-(+)-4-{2-[5-(2-fluoro-3-methoxyphenyl)-3-(2-fluoro-6-[trifluoromethyl]benzyl)-4-methyl-2,6-dioxo-3,6-dihydro-2H-pyrimidin-1-yl]-1-phenylethylamino}butyrate (elagolix), a potent and orally available nonpeptide antagonist of the human gonadotropin-releasing hormone receptor. J Med Chem 2008;51:7478-85
  • Struthers RS, Nicholls AJ, Grundy J, Suppression of gonadotropins and estradiol in premenopausal women by oral administration of the nonpeptide gonadotropin-releasing hormone antagonist elagolix. J Clin Endocrinol Metab 2009;94:545-51

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.